December 07, 2001 09:51
GenoMed, Inc. Adds Tony Frudakis, Ph.D. to Scientific Advisory Board
SARASOTA, Fla.--(BUSINESS WIRE)--Dec. 7, 2001--GenoMed Inc.--("the Company" or "GenoMed") (Pink Sheets:GMED) a St. Louis, Missouri based medical genomics biotechnology company, announced today that Tony Frudakis, Ph.D., has joined the Company's Scientific Advisory Board. Dr. Frudakis is the Chief Executive and Scientific Officer of DNAPrint Genomics, Inc., (OTCBB:DNAP), a Sarasota, Florida based genomics company. Dr. Frudakis was recently honored as the Most Influential Scientist in the SNP and Genotyping sector by Genome Technology Magazine.
Dr. Tony Frudakis is a Phi Beta Kappa, Magna Cumme Laude graduate of the University of California. He received his doctorate degree in molecular and cell biology from the University of California, Berkeley, and has 14 years of experience as a molecular biologist. Dr. Frudakis' career has resulted in a patent portfolio of over 350 unique genes and 2 products.
Jerry White, GenoMed's President & Chief Executive Officer, stated that, "It is a great honor to welcome Dr. Frudakis to our Scientific Advisory Board. His experience and expertise within the area of medical genetics is a tremendous asset to our Scientific Advisory Board and we are very fortunate to have him as a member of our advisory board."
"Not only does population genetics need more horsepower, but it needs the type of horsepower that GenoMed will provide. Although GenoMed's research will differ from that of DNAPrint, it is worthy research that addresses a real need in the field. I am pleased to have a chance to interact with GenoMed in a scientifically meaningful way," said Tony Frudakis, Ph.D.
About GenoMed
GenoMed was founded with the sole purpose of translating knowledge of disease genes into better patient outcomes as rapidly and as safely as possible. The Company's business model specifically links improved patient outcomes to Company revenues through clinical treatment and genetic diagnoses of diseases.
For additional information please visit genomedics.com and/or contact Craig Hall at 941/366-6677 or email at chall@floridafunds.com.
This press release contains forward looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including those statements pertaining to the beneficial nature of Tony Frudakis joining the Company Scientific Advisory Board. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those projected in the forward looking statements as a result of a number of risks and uncertainties. Among other things, competition from existing or new competitors will impact our business; our research and development is subject to economic, regulatory, governmental, and technological factors. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. Unless otherwise required by applicable law, we do not undertake, and specifically disclaims any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.
CONTACT: GenoMed, Inc., Sarasota
Craig Hall, 941/366-6677
chall@floridafunds.com
genomedics.com |
